This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

ATENÇÃO!

COMUNICADO IMPORTANTE

Com o objetivo de garantir a comunicação educacional segura sobre nossos produtos, esclarecemos que a Novo Nordisk não incentiva e/ou compactua com qualquer tipo de veiculação midiática acerca da utilização de nossas moléculas para indicações ainda não previstas em bula e, portanto, ainda não aprovadas pela Agência Nacional de Vigilância Sanitária (ANVISA). Assim, reiteramos que reportagens ou publicações com esse teor não são endossadas pela Novo Nordisk.

 

Pedimos que em caso de dúvidas sobre nossas moléculas, dirijam-se aos seguintes canais para obtenção de informações:

 1. visite a nossa sessão Educacional, onde você poderá encontrar informações científicas acuradas;

2. nos contate através do SIC (Scientific Information Service): sic.br@novonordisk.com

Bate-Papo Cardiometabólico: Como ter resultados inéditos na sua prática clínica com diabetes e obesidade?

Neste primeiro bate-papo, o Dr. Marcio Krakauer, Dr. Bruno Mioto e Dra. Renata Castro irão discutir sobre o legado da semaglutida, uma molécula que está há mais de 6 anos no mercado e representa uma evolução no tratamento do DM2, obesidade e sobrepeso e na redução do risco cardiovascular.1,7,33,46


Os palestrantes irão aprofundar uma discussão sobre: como tratar essas doenças na prática clínica, como começar a usar a semaglutida com os pacientes, como atingir resultados transformadores, as indicações e aspectos práticos de cada medicamento, e, por fim, a importância do acompanhamento e adesão do paciente, através de exemplos práticos.


A semaglutida tem mais de 60 estudos (clínicos, randomizados e vida real) e aproximadamente 50 mil pacientes avaliados, uma molécula robusta com diversas possibilidades.2-62


Não perca!

Bate-Papo Cardiometabólico

Data

{{getCountryDateFormat("27/05/2025" + " - " + "27/05/2025", "", "", "às 19:00 - 20:00")}}



Evento destinado exclusivamente a profissionais de saúde habilitados a prescrever e/ou dispensar medicamentos.

1.

DIÁRIO OFICIAL DA UNIÃO Publicado em: 06/08/2018; Edição: 150; Seção: 1 – Suplemento; Página: 4;

2.

SUSTAIN 1. Sorli C. et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes. The Lancet Diabetes & Endocrinology, 01 Apr 2017, Vol.5, Issue 4, pages 251 – 260;

3.

SUSTAIN 2. Ahrén, Bo. et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes. The Lancet Diabetes & Endocrinology, 01 May 2017, Vol.5, Issue 5, pages 341 – 354;

4.

SUSTAIN 3. Ahmann, AJ. et al. Efficacy and Safety of Once- Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes. Diabetes care, 01 Feb 2018, Vol.41, Issue 2, pages 258 – 266;

5.

SUSTAIN 4. Aroda, VR. et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes. The Lancet Diabetes & Endocrinology, 01 May 2017, Vol.5, Issue 5, pages 355 – 366;

6.

SUSTAIN 5. Rodbard, HW. et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes . The Journal of Clinical Endocrinology & Metabolism, 01 Jun 2018, Vol.103, Issue 6, pages 2291 – 2301;

7.

SUSTAIN 6. Marso, SP. et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England journal of medicine, 10 Nov 2016, Vol. 375, Issue 19, pages 1834 – 1844.

8.

SUSTAIN 7. Pratley, RE. et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes The Lancet Diabetes & Endocrinology, 01 Apr 2018, Vol.6, Issue 4, pages 275 – 286.

9.

SUSTAIN 8. Lingvay, I. et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes. The Lancet Diabetes & Endocrinology, 01 Nov 2019, Vol.7, Issue 11, pages 834 – 844.

10.

SUSTAIN 9. Zinman, B. et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes. The Lancet Diabetes & Endocrinology, 01 May 2019, Vol.7, Issue 5, pages 356 – 367.

11.

SUSTAIN 10. Capehorn, MS. et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes. Diabetes & metabolism, 01 Apr 2020, Vol.46, Issue 2, pages 100 – 109.

12.

SUSTAIN 11. Kellerer M, et al. Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes. Diabetes Obesity Metabolism. 2022 Sep;24(9):1788–99.

13.

SUSTAIN-JP. Seino Y, et al. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obesity Metabolism. 2018 Feb;20(2):378–88.

14.

SUSTAIN China. Ji L, et al. Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes in China. Diabetes Obesity Metabolism. 2021 Feb;23(2):404–14.

15.

SUSTAIN-JP add-on. Kaku K, et al. Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes. Diabetes Obesity Metabolism. 2018 May;20(5):1202–12.

16.

SUSTAIN FORTE. Frías, Juan P, et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes. The Lancet Diabetes & Endocrinology, 01 Sep 2021, Vol.9, Issue 9, pages 563 - 574.

17.

REMODEL. Bjornstad P, et al. Mo399: remodel: a mechanistic trial evaluating the effects of semaglutide on the kidneys in people with type 2 diabetes and chronic kidney disease. Nephrology Dialysis Transplantation. 2022 May 3;37(Supplement_3): gfac070.013.

18.

FOCUS. Sharma A, et al. Semaglutide and the risk of diabetic retinopathy—current perspective. Eye. 2022 Jan;36(1):10–1.

19.

FLOW. Perkovic V, et al. Effects of semaglutide on chronic kidneydisease in patients with type 2 diabetes. N Engl J Med. 2024 Jul 11;391(2):109–21.

20.

PIONEER 1. Aroda, VR. et al. Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes care, 01 Sep 2019, Vol.42, Issue 9, pages 1724 - 1732.;

21.

PIONEER 2. Rodbard, HW. et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: Diabetes care, 01 Dec 2019, Vol.42, Issue 12, pages 2272 – 2281.

22.

PIONEER 3. Rosenstock, J. et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults with Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea. JAMA: the journal of the American Medical Association, 16 Apr 2019, Vol.321, Issue 15, pages 1466 – 1480. 

23.

PIONEER 4. Pratley, R. et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabet9es. The Lancet, 06 Jul 2019, Vol.394, Issue 10192, pages 39 – 50.

24.

PIONEER 5. Mosenzon, O. et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment. The Lancet Diabetes & Endocrinology, 01 Jul 2019, Vol.7, Issue 7, pages 515 – 527.

25.

PIONEER 6. Husain, M. et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England journal of medicine, 29 Aug 2019, Vol.381, Issue 9, pages 841 -851

26.

PIONEER 7. Pieber, TR. et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes. The Lancet Diabetes & Endocrinology, 01 Jul 2019, Vol.7, Issue 7, pages 528 – 539.

27.

PIONEER 8. Zinman, B. et al. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin with or Without Metformin in Patients With Type 2 Diabetes.Diabetes care, 01 Dec 2019, Vol.42, Issue 12, pages 2262 – 2271.

28.

PIONEER 9. Yamada Y, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes. The Lancet Diabetes & Endocrinology. 2020 May;8(5):377–91.

29.

PIONEER 10. Yabe D, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes. The Lancet Diabetes & Endocrinology. 2020
May;8(5):392–406.

30.

PIONEER 11. Wang W, Bain SC, Bian F, Chen R, Gabery S, Huang S, et al. Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes. Diabetologia. 2024 Sep;67(9):1783–99.

31.

PIONEER 12. Ji L, et al. Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin. Diabetologia 2024 ep;67(9):1800–16.

32.

PIONEER PLUS. Aroda, Vanita R, et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes. The Lancet, 26 Aug 2023, Vol.402, Issue 10403, pages 693 – 704.

33.

SMcGuire DK., et al. N Engl J Med. 2025: https://www.nejm.org/doi/full/10.1056/NEJMoa2501006.

34.

STEP 1. Wilding, John P.H., et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 18 Mar 2021, Vol. 384, Issue 11, pages 989 – 1002.

35.

STEP 2. Davies, M. et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes. The Lancet, 13 Mar 2021, Vol.397, Issue 10278, pages 971 - 984.

36.

STEP 3. Wadden, Thomas A., et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA : the journal of the American Medical Association, 13 Apr 2021, Vol.325, Issue 14, pages 1403 – 1413.

37.

STEP 4. Rubino, D. et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA : the journal of the American Medical Association, 13 Apr 2021, Vol.325, Issue 14,pages 1414-1425.

38.

STEP 5. Garvey, W. Timothy, et al. Two-year effects of semaglutide in adults with overweight or obesity. Nature medicine, 10 Oct 2022, Vol.28, Issue 10, pages 2083 – 2091.

39.

STEP 6. Kadowaki, T. et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population. The Lancet Diabetes & Endocrinology, 01 Mar 2022, Vol.10, Issue 3, pages 193 – 206.

40.

STEP 7. Mu Y, et al. Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity. Diabetes & Endocrinology. 2024 Mar;12(3):184–95.

41.

STEP 8. Rubino, D. M. et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA : the journal of the American Medical Association, 11 Jan 2022, Vol. 327, Issue 2, pages 138 – 150.

42.

STEP 9. Bliddal H, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024 Oct 31;391(17):1573–83.

43.

STEP 10. McGowan BM, et al. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes. The Lancet Diabetes & Endocrinology. 2024 Sep;12(9):631–42.

44.

STEP TEENS. Weghuber,D. et al. Once-Weekly Semaglutide in Adolescents with Obesity. The New England journal of medicine, 15 Dec 2022, Vol. 387, Issue 24, pages 2245 – 2257.

45.

STEP HFpEF DM. Kosiborod MN, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024 Apr 18;390(15):1394–407.

46.

SELECT. Lincoff, A. Michael, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England journal of medicine, 11 Nov 2023.

SELECT. Lincoff, A. Michael, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England journal of medicine, 11 Nov 2023.
47.

OASIS 1. Knop, Filip K, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 26 Aug 2023, Vol.402, Issue 10403, pages 705 - 719.

48.

PIONEER REAL Sweden. Catrina, SB. et al. A Multicentre, Prospective, Real-World Observational Study of Oral Semaglutide Use in Adults with Type 2 Diabetes in Swedish Clinical Practice. Diabetes Ther 15, 2079–2095 (2024).

49.

PIONEER REAL Canada. Jain AB, et al. Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada. Diabetes Obes Metab. 2024 May;26(5):1799-1807.

50.

PIONEER REAL Netherlands. van Houtum W, et al. Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes. Diabetes Ther. 2024 Aug;15(8):1749-1768. 76. PIONEER REAL Switzerland. Kick A, et al. Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes. Diabetes Ther. 2024 Mar;15(3):623-637.

51.

PIONEER REAL Japan. Yabe D, et al. Primary results from a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice. J Diabetes Investig. 2024 Aug 22.

52.

PIONEER REAL UK Saravanan P, et al. A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes. Adv Ther. 2024 Sep 24.

53.

SURE. Yale JF, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups. BMJ Open Diab Res Care. 2022 Apr;10(2):e002619.

54.

SURE Denmark/ Sweden. Rajamand Ekberg, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes. Primary Care Diabetes. 2021 Oct;15(5):871–8.

55.

SURE Switzerland. Rudofsky G, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes. Diabetes Research and Clinical Practice. 2021 Aug;178:108931.

56.

SURE UK. Holmes P, et al. Real-world use of once-weekly semaglutide in type 2 diabetes.Diabetes Ther. 2021 Nov;12(11):2891–905.

57.

SURE NETHERLANDS. Wolffenbuttel BHR, Brugts MP, Catarig AM, Clark A, Kok M, Lieverse AG, et al. Once-weekly semaglutide use in type 2 diabetes. Adv Ther. 2023 Mar;40(3):920–33.

58.

SURE GERMANY. Menzen M, et al. Real-world use of once-weekly semaglutide in type 2 diabetes. Exp Clin Endocrinol Diabetes. 2023 Apr;131(04):205–15.

59.

SURE SPAIN. Bellido V, et al. Once-weekly semaglutide use in patients with type 2 diabetes. JCM. 2022 Aug 23;11(17):4938.

60.

SURE ITALY. Napoli R, et al. Once‐weekly semaglutide use in patients with type 2 diabetes: Real‐world data from the SURE Italy observational study. Diabetes Obesity Metabolism. 2023 Jun;25(6):1658–67.

61.

REALISE-DM Jain AB, Kanters S, Khurana R, Kissock J, Severin N, Stafford SG. Real-world effectiveness analysis of switching from liraglutide or dulaglutide to semaglutide in patients with type 2 diabetes mellitus. Diabetes Ther. 2021 Feb;12(2):527–36.

62.

STEP HFpEF. Kosiborod, Mikhail N , et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. The New England journal of medicine, 21 Sep 2023, Vol. 389, Issue 12, pages 1069 – 1084.

ESCOLHA UMA OPÇÃO